• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活体供者的可用性优化了高危等待肝移植肝硬化患者的手术时机。

Availability of living donor optimizes timing of liver transplant in high-risk waitlisted cirrhosis patients.

机构信息

Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Ontario M5G 2N2, Canada.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Toronto, Ontario M5G 2N2, Canada.

出版信息

Aging (Albany NY). 2023 Sep 2;15(17):8594-8612. doi: 10.18632/aging.204982.

DOI:10.18632/aging.204982
PMID:37665673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10522397/
Abstract

Liver transplant (LT) candidates have become older and frailer, with growing Non-alcoholic steatohepatitis (NASH) and comorbid disease burden in recent years, predisposing them for poor waitlist outcomes. We aimed to evaluate the impact of access to living donor liver transplantation (LDLT) in waitlisted patients at highest risk of dropout. We reviewed all adult patients with decompensated cirrhosis listed for LT from November 2012 to December 2018. Patients with a potential living donor (pLD) available were identified. Survival analyses with Cox Proportional Hazards models and time to LT with Competing risk models were performed followed by prediction model development. Out of 860 patients who met inclusion criteria, 360 (41.8%) had a pLD identified and 496 (57.6%) underwent LT, out of which 170 (34.2%) were LDLT. The benefit of pLD was evident for all, but patients with moderate to severe frailty at listing (interaction = 0.03), height <160 cm (interaction = 0.03), and Model for end stage liver disease (MELD)-Na score <20 (interaction < 0.0001) especially benefited. Our prediction model identified patients at highest risk of dropout while waiting for deceased donor and most benefiting of pLD (time-dependent area under the receiver operating characteristic curve 0.82). Access to LDLT in a transplant program can optimize the timing of transplant for the increasingly older, frail patient population with comorbidities who are at highest risk of dropout.

摘要

肝移植 (LT) 候选者的年龄和身体虚弱程度不断增加,近年来非酒精性脂肪性肝炎 (NASH) 和合并症的疾病负担也在增加,这使他们在等待名单上的预后较差。我们旨在评估在等待名单上风险最高的患者中获得活体供肝移植 (LDLT) 的机会对他们的影响。我们回顾了 2012 年 11 月至 2018 年 12 月期间所有因失代偿性肝硬化而接受 LT 登记的成年患者。确定了有潜在活体供体 (pLD) 的患者。采用 Cox 比例风险模型进行生存分析和竞争风险模型进行 LT 时间分析,然后进行预测模型的开发。在符合纳入标准的 860 名患者中,有 360 名 (41.8%) 确定了 pLD,496 名 (57.6%) 接受了 LT,其中 170 名 (34.2%) 是 LDLT。pLD 的益处对所有人都是明显的,但对于在登记时身体虚弱程度中等至重度的患者(交互作用=0.03)、身高<160cm 的患者(交互作用=0.03)和模型终末期肝病评分 (MELD)-Na 评分<20 的患者(交互作用<0.0001)尤其有益。我们的预测模型确定了在等待死亡供体时最有可能退出的患者,并且最受益于 pLD(时间依赖性接受者操作特征曲线下面积 0.82)。在移植项目中获得 LDLT 可以优化患有合并症的年龄较大、身体虚弱的患者群体的移植时机,这些患者最有可能退出。

相似文献

1
Availability of living donor optimizes timing of liver transplant in high-risk waitlisted cirrhosis patients.活体供者的可用性优化了高危等待肝移植肝硬化患者的手术时机。
Aging (Albany NY). 2023 Sep 2;15(17):8594-8612. doi: 10.18632/aging.204982.
2
Sex Disparity in Liver Transplant and Access to Living Donation.性别差异与肝移植和活体捐赠机会
JAMA Surg. 2021 Nov 1;156(11):1010-1017. doi: 10.1001/jamasurg.2021.3586.
3
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.活体供肝移植可以解决原发性硬化性胆管炎患者在移植机会方面的差异。
Hepatol Commun. 2023 Aug 3;7(8). doi: 10.1097/HC9.0000000000000219. eCollection 2023 Aug 1.
4
Natural history of NASH cirrhosis in liver transplant waitlist registrants.NASH 肝硬化在肝移植候补者中的自然史。
J Hepatol. 2023 Oct;79(4):1015-1024. doi: 10.1016/j.jhep.2023.05.034. Epub 2023 Jun 10.
5
Survival Benefit of Living-Donor Liver Transplant.活体肝移植的生存获益。
JAMA Surg. 2022 Oct 1;157(10):926-932. doi: 10.1001/jamasurg.2022.3327.
6
Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.终末期肝病模型评分低的肝移植候选者的结局
Liver Transpl. 2015 Nov;21(11):1403-9. doi: 10.1002/lt.24307.
7
Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End-Stage Liver Disease and Hepatorenal Syndrome.高终末期肝病和肝肾综合征模型中活体与死体供肝肝移植的生存获益分析。
Hepatology. 2021 Jun;73(6):2441-2454. doi: 10.1002/hep.31584. Epub 2021 May 4.
8
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.在终末期肝病模型分配时代,活体捐赠对肝移植受者生存获益的影响。
Hepatology. 2011 Oct;54(4):1313-21. doi: 10.1002/hep.24494.
9
Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area.在乙肝流行地区,对终末期肝病模型评分≥35的患者进行活体供肝与尸体供肝肝移植的短期和长期疗效比较
Ann Surg. 2017 Jan;265(1):173-177. doi: 10.1097/SLA.0000000000001671.
10
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.成人对成人活体肝移植队列研究中的复发性原发性硬化性胆管炎:活体供肝与尸体供肝受者的危险因素比较
Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.

引用本文的文献

1
Vascular outflow reconstruction in right lobe living donor liver transplantation with and without middle hepatic vein.右半肝活体肝移植中伴与不伴肝中静脉的血管流出道重建
Updates Surg. 2025 Jan 15. doi: 10.1007/s13304-024-02051-7.
2
Engagement With Sports After Solid Organ Transplant.实体器官移植后的体育活动参与情况
Cureus. 2024 Sep 4;16(9):e68622. doi: 10.7759/cureus.68622. eCollection 2024 Sep.

本文引用的文献

1
Awarding additional MELD points to the shortest waitlist candidates improves sex disparity in access to liver transplant in the United States.给等待名单中等待时间最短的候选人额外加分配额,可改善美国肝脏移植中性别差异导致的可及性问题。
Am J Transplant. 2022 Dec;22(12):2912-2920. doi: 10.1111/ajt.17159. Epub 2022 Aug 3.
2
Sex Disparity in Liver Transplant and Access to Living Donation.性别差异与肝移植和活体捐赠机会
JAMA Surg. 2021 Nov 1;156(11):1010-1017. doi: 10.1001/jamasurg.2021.3586.
3
OPTN/SRTR 2019 Annual Data Report: Liver.OPTN/SRTR 2019 年度数据报告:肝脏。
Am J Transplant. 2021 Feb;21 Suppl 2:208-315. doi: 10.1111/ajt.16494.
4
Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources.在分配稀缺医疗资源时使用临床衰弱量表。
Can Geriatr J. 2020 Sep 1;23(3):210-215. doi: 10.5770/cgj.23.463. eCollection 2020 Sep.
5
Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma.年龄对伴有和不伴有肝细胞癌的肝移植候选者的影响差异。
Liver Transpl. 2020 Mar;26(3):349-358. doi: 10.1002/lt.25662. Epub 2019 Nov 20.
6
Identifying a clinically relevant cutoff for height that is associated with a higher risk of waitlist mortality in liver transplant candidates.确定与肝移植候选者等待名单死亡率升高相关的临床相关身高切点。
Am J Transplant. 2020 Mar;20(3):852-854. doi: 10.1111/ajt.15644. Epub 2019 Nov 4.
7
Multicenter Study of Age, Frailty, and Waitlist Mortality Among Liver Transplant Candidates.多中心研究:肝移植候选者的年龄、衰弱与等待期死亡率。
Ann Surg. 2020 Jun;271(6):1132-1136. doi: 10.1097/SLA.0000000000003207.
8
Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study.在一项多中心研究中,虚弱与等待名单死亡率相关,与腹水和肝性脑病无关。
Gastroenterology. 2019 May;156(6):1675-1682. doi: 10.1053/j.gastro.2019.01.028. Epub 2019 Jan 19.
9
Impact of sepsis and non-communicable diseases on prognostic models to predict the outcome of hospitalized chronic liver disease patients.脓毒症和非传染性疾病对预测住院慢性肝病患者预后模型的影响。
World J Hepatol. 2018 Dec 27;10(12):944-955. doi: 10.4254/wjh.v10.i12.944.
10
Age and liver transplantation.年龄与肝移植。
J Hepatol. 2019 Apr;70(4):745-758. doi: 10.1016/j.jhep.2018.12.009. Epub 2018 Dec 18.